Skip to content

Continuous Glucose Monitoring for Glucose and Weight Management in Prediabetes and Non-severe Type 2 Diabetes: A Prospective Community-based (Workplace) Cohort Study

Continuous Glucose Monitoring for Glucose and Weight Management in Prediabetes and Non-severe Type 2 Diabetes

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06542627
Enrollment
420
Registered
2024-08-07
Start date
2023-05-22
Completion date
2025-12-31
Last updated
2024-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PreDiabetes, Diabetes Mellitus, Type 2

Brief summary

This study aimed to evaluate the effectiveness of use of Continuous Glucose Monitoring (CGM), combined with personalized dietary education and use of smartphone applications in improving glucose control and weight management.

Interventions

Glycemic control was monitored using CGM data for two weeks, followed by individualized dietary education.

Sponsors

Samsung Electronics
CollaboratorINDUSTRY
Kangbuk Samsung Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects over the age of 19 * Patients with type 2 diabetes * Fasting blood glucose ≥ 126 mg/dL or * HbA1c ≥ 6.5% or * Type 2 diabetes by clinical history and treated with antidiabetic medications or lifestyle Modifications * Patients with prediabetes * Fasting blood glucose 100-125 mg/dL * HbA1c 5.7-6.4% * Willing to participate in the study

Exclusion criteria

* Subjects less than 19 years old * Patients with type 1 diabetes * Pregnant at the time of screening or planning to become pregnant during the study * Severe chronic diseases such as cancer, stroke, proliferative retinopathy, myocardial infarction, chronic renal disease, or amputation of a diabetic foot * Diagnosed with or treated for myocardial infarction, stroke, end-stage renal disease, liver failure, or chronic lung disease within the past year * Severe liver disease (e.g., cancer, liver cirrhosis, hepatitis B, hepatitis C) * Diseases of the biliary tract, thyroid disorders, autoimmune disorders, or acute infections * Planning to be admitted to a hospital within 2 months * Unable to participate in the mobile intervention study as determined by the investigator

Design outcomes

Primary

MeasureTime frameDescription
HbA1c8weeks after interventionHbA1c assessed by blood test after 2-week use of CGM and dietary education

Secondary

MeasureTime frameDescription
Fasting blood glucose8weeks after interventionFasting blood glucose, assessed by blood test after 2-week use of CGM and dietary education
Lipid profiles8weeks after interventionLipid profiles (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride), assessed by blood test after 2-week use of CGM and dietary education
Body weight8weeks after interventionBody weight assessed by blood test after 2-week use of CGM and dietary education
Pre- and post-intervention questionnaire: Diabetes Treatment Satisfaction Questionnaire (DTSQ)8weeks after interventionPre- and post-intervention questionnaires, assessed by self-reported survey. The questionnaire is composed of three parts. * total satisfaction (minimum 0, maximum 36, higher scores mean a better outcome.) * perceived hyperglycaemia (minimum 0, maximum 6, higher scores mean a worse outcome.) * perceived hypoglycaemia (minimum 0, maximum 6, higher scores mean a worse outcome.)
Pre- and post-intervention questionnaire: Summary of Diabetes Self-Care Activities Questionnaire (SDSCAS).8weeks after interventionPre- and post-intervention questionnaires, assessed by self-reported survey. The questionnaire is composed of five parts. * diet (values: minimum 0, maximum 28, higher scores mean a better outcome.) * exercise (minimum 0, maximum 14, higher scores mean a better outcome.) * blood sugar check-up (values: minimum 0, maximum 14, higher scores mean a better outcome.) * foot care (minimum 0, maximum 14, higher scores mean a better outcome.) * smoking (minimum 0, maximum 1, higher scores mean a worse outcome.)

Countries

South Korea

Contacts

Primary ContactPark
cydoctor68@gmail.com0220011550
Backup ContactKo
sjaks999@gmail.com0220011550

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026